Skip to Main Content

Everyone loves a winner, but who are they? Let us help you figure it out. Each Friday, we will provide a quick rundown of individuals and companies that accomplished something worth noting. But to be fair, we will also point out those who, well, had a rough time. And if you have a nomination, send us a note. We would not want anyone to feel left out, even the losers.


The makers of ovarian cancer drugs: Clovis Oncology won approval for its PARP drug for ovarian cancer – and, to boot, two months earlier than scheduled. And Tesaro managed to snag priority review designation from the FDA for its own ovarian cancer medication.  Of course, only time will tell if ovarian cancer patients themselves will find these drugs to be affordable and effective and become winners too.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!